Literature DB >> 27981615

Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease.

Fernando Bril1, Diana Barb1, Paola Portillo-Sanchez1, Diane Biernacki1, Romina Lomonaco1, Amitabh Suman2, Michelle H Weber3, Jeffrey T Budd4, Maria E Lupi5, Kenneth Cusi1,6.   

Abstract

The cut-off point of intrahepatic triglyceride (IHTG) content to define nonalcoholic fatty liver disease (NAFLD) by proton magnetic resonance spectroscopy (1 H-MRS) was established based on the 95th percentile in a group of healthy individuals (i.e., ≥5.56%). Whether this threshold correlates with metabolic and histological changes and whether a further accumulation of IHTG is associated with worsening of these parameters has not been properly assessed in a large cohort of patients. In this cross-sectional study, 352 subjects were carefully characterized with the following studies: liver 1 H-MRS; euglycemic insulin clamp with measurement of glucose turnover; oral glucose tolerance test; and a liver biopsy. Hepatic insulin sensitivity (suppression of endogenous glucose production by insulin) was affected early on after IHTG content was ∼1.5% and remained uniformly impaired (∼40%-45%), regardless of further IHTG accumulation. Skeletal muscle insulin sensitivity showed a gradual impairment at low degrees of IHTG accumulation, but remained unchanged after IHTG content reached the ∼6 ± 2% threshold. A similar pattern was observed for metabolic changes typically associated with NAFLD, such as hypertriglyceridemia and low high-density lipoprotein cholesterol (HDL-C). In contrast, adipose tissue insulin sensitivity (suppression of free fatty acids by insulin) showed a continuous worsening across the spectrum of IHTG accumulation in NAFLD (r = -0.38; P < 0.001). Histological severity of liver disease (inflammation, ballooning, and fibrosis) was not associated with the amount of IHTG content.
CONCLUSION: IHTG accumulation is strongly associated with adipose tissue insulin resistance (IR), supporting the current theory of lipotoxicity as a driver of IHTG accumulation. Once IHTG accumulation reaches ∼6 ± 2%, skeletal muscle IR, hypertriglyceridemia, and low HDL-C become fully established. Histological activity appears to have an early threshold and is not significantly influenced by increasing amounts of IHTG accumulation. (Hepatology 2017;65:1132-1144).
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27981615     DOI: 10.1002/hep.28985

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  61 in total

Review 1.  Innate immune regulatory networks in hepatic lipid metabolism.

Authors:  Lan Bai; Hongliang Li
Journal:  J Mol Med (Berl)       Date:  2019-03-19       Impact factor: 4.599

2.  Lipids and ketones dominate metabolism at the expense of glucose control in pulmonary arterial hypertension: a hyperglycaemic clamp and metabolomics study.

Authors:  Jacob T Mey; Adithya Hari; Christopher L Axelrod; Ciarán E Fealy; Melissa L Erickson; John P Kirwan; Raed A Dweik; Gustavo A Heresi
Journal:  Eur Respir J       Date:  2020-04-09       Impact factor: 16.671

3.  Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.

Authors:  Elizabeth M Brunt; David E Kleiner; Laura A Wilson; Arun J Sanyal; Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2019-03-07       Impact factor: 17.425

Review 4.  Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.

Authors:  Sven Francque; Gyongyi Szabo; Manal F Abdelmalek; Christopher D Byrne; Kenneth Cusi; Jean-François Dufour; Michael Roden; Frank Sacks; Frank Tacke
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-22       Impact factor: 46.802

5.  Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.

Authors:  Yuval A Patel; Elizabeth J Gifford; Lisa M Glass; Marsha J Turner; Byungjoo Han; Cynthia A Moylan; Steve Choi; Ayako Suzuki; Dawn Provenzale; Christine M Hunt
Journal:  Dig Dis Sci       Date:  2018-05-19       Impact factor: 3.199

6.  Feasibility of balanced steady-state free precession sequence at 1.5T for the evaluation of hepatic steatosis in obese children and adolescents.

Authors:  Hong-Xi Zhang; Jun-Fen Fu; Can Lai; Feng-Yu Tian; Xiao-Li Su; Ke Huang
Journal:  Eur Radiol       Date:  2018-04-30       Impact factor: 5.315

7.  Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes.

Authors:  Diana Barb; Fernando Bril; Srilaxmi Kalavalapalli; Kenneth Cusi
Journal:  J Clin Endocrinol Metab       Date:  2019-08-01       Impact factor: 5.958

8.  Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.

Authors:  Fernando Bril; Paola Portillo Sanchez; Romina Lomonaco; Beverly Orsak; Joan Hecht; Fermin Tio; Kenneth Cusi
Journal:  J Clin Endocrinol Metab       Date:  2017-08-01       Impact factor: 5.958

9.  Influence of adiposity, insulin resistance, and intrahepatic triglyceride content on insulin kinetics.

Authors:  Gordon I Smith; David C Polidori; Mihoko Yoshino; Monica L Kearney; Bruce W Patterson; Bettina Mittendorfer; Samuel Klein
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

10.  Effects of sprint interval training on ectopic lipids and tissue-specific insulin sensitivity in men with non-alcoholic fatty liver disease.

Authors:  Jack A Sargeant; Stephen Bawden; Guruprasad P Aithal; Elizabeth J Simpson; Ian A Macdonald; Mark C Turner; Jessica Cegielski; Kenneth Smith; James L Dorling; Penny A Gowland; Myra A Nimmo; James A King
Journal:  Eur J Appl Physiol       Date:  2018-02-06       Impact factor: 3.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.